DDInter837 DDInter1147
Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi®.
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Golimumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Golimumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Golimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nifedipine
Golimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diiodohydroxyquinoline
Golimumab {u} may lead to a major life threatening interaction when taken with {v} Cyclophosphamide
Golimumab {u} may lead to a major life threatening interaction when taken with {v} Avapritinib
Golimumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Golimumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Golimumab may lead to a major life threatening interaction when taken with Cyclophosphamide
Golimumab may lead to a major life threatening interaction when taken with Avapritinib